|6 Months Ended|
Jun. 30, 2017
|Notes to Financial Statements|
|Note 15 - CONCENTRATIONS||
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
The Company's revenues earned from sale of products and services for the three months ended June 30, 2016 included 14%, 14%, 14% and 14% (aggregate of 56%) from four customers of the Company's total revenues.
The Company's revenues earned from sale of products and services for the six months ended June 30, 2016 included 11%, 15% and 10% (aggregate of 36%) from three customers of the Company's total revenues.
The Company did not have a concentration for the three and six months ended June 30, 2017.
Two customers accounted for 17% and 11% (aggregate of 28%) of the Company's total accounts receivable at June 30, 2017 and three customers accounted for 27%, 11% and 18% (aggregate of 56%) of the Company's total accounts receivable at December 31, 2016.
The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
Reference 1: http://www.xbrl.org/2003/role/presentationRef